Investor Presentation First Nine Months of 2022
43
Investor presentation First nine months of 2022
Novo Nordisk has 56% of the global GLP-1 market, while GLP-1
penetration of diabetes volume varies across regions
80%
60%
40%
20%
0%
Novo NordiskⓇ
GLP-1 market growth and Novo Nordisk market share
4% of total diabetes prescriptions use a GLP-1 with large
differences across markets
Million scripts
Aug
2019
Global: 4%
63%
8
62%
OZEMPİC
semaglutide injection
RYBELSUS
semaglutide tablets
56%
6
52%
4
2
0
Aug
2017
2022
-NN market share
NN share of growth
EMEA
-Market growth
NN growth
North America
Patient share based on data for the USA, the UK, Germany and France only.
Source: IQVIA MAT value (spot rate), Aug 2022
Region China
10%
2%
2%
4%
2022
Rest of World
GLP-1 share of diabetes prescription
EMEA: Europe, Middle East and Africa; Region China covers Mainland China, Taiwan, and Hong Kong
Source: IQVIA MAT, Aug 2022View entire presentation